Table 1 Clinical features of stage 4 NB patients
From: An 18 gene expression-based score classifier predicts the clinical outcome in stage 4 neuroblastoma
Variables | Seeger cohorta | Versteeg cohortb | Validation cohort 1c | Validation cohort 2d |
|---|---|---|---|---|
n = 102 | n = 40 | n = 214 | n = 27 | |
Sex | ||||
 Male | N/A | 24 (60 %) | 122 (60.1) | 13 (48.1) |
 Female | N/A | 16 (40 %) | 81 (39.9) | 14 (51.8) |
 N/A |  |  | 12 |  |
Age | ||||
 Median (years) |  | 2.5 | 2.7 | 2.6 |
 <18 months | N/A | 8 (20.0 %) | 68 (31.8 %) | 8 (29.6) |
 ≥18 months | N/A | 32 (30.0 %) | 146 (68.2 %) | 19 (70.4) |
MYCN amplification | ||||
 Yes | 0 (0 %) | 15 (37.5 %) | 68 (31.9 %) | 14 (51.8) |
 No | 102 (100 %) | 25 (62.5 %) | 145 (68.1 %) | 13 (48.1) |